Sharma Aman, Jain Manish, Yadav Rahul, Rathi Priyanka
Department of Pharmacology, RUHS College of Medical Sciences and Associated Group of Hospitals, Jaipur, Rajasthan, India.
Department of Plastic Surgery, Mahatma Gandhi Medical College and Associated Group of Hospitals, Jaipur, Rajasthan, India.
J Family Med Prim Care. 2021 Sep;10(9):3387-3394. doi: 10.4103/jfmpc.jfmpc_724_21. Epub 2021 Sep 30.
In the prevailing COVID-19 pandemic, the Indian healthcare system has worked hard towards restricting the adverse outcomes to the least possible figures. The present study aims to share the experience of a COVID-dedicated tertiary care government hospital in Northern India of managing COVID-19 patients with comorbidities.
A retrospective, observational study was conducted in a COVID-dedicated tertiary health care government hospital in Northern India. Details on sociodemographic data, hospital admission data, and drug utilization pattern of all laboratory-confirmed COVID-19 patients of all age groups, either gender, having comorbidity (s), and admitted between April and September, 2020 were noted and evaluated.
Among the total study participants (N = 406), 2868 drugs were prescribed. Out of these, 2336 were used for the management of symptoms of COVID-19 and 532 were used for the management of coexistent comorbidity (s). For COVID-19 symptoms, the most commonly prescribed class of drugs were antimicrobials (853, 36.52%), followed by nonsteroidal antiinflammatory drugs (374, 16.01%), proton pump inhibitors (299, 12.80%), antihistamines (232, 9.93%), immunosuppressant drugs (103, 4.41%), and others. For comorbidities most commonly prescribed were antihypertensive (310, 58.60%) drugs, followed by antidiabetic drugs (166, 31.38%), bronchodilators (34, 6.43%), thyroid hormones (11, 2.08%), immunosuppressant drugs (7, 1.32%).
The most frequently prescribed antihypertensives were calcium channel blockers (CCBs) and least prescribed was beta blocker+CCB. Among the antidiabetic drugs, most frequently prescribed was insulin and least prescribed was DPP-4 inhibitors and Biguanide+DPP-4 inhibitor both.
在当前的新冠疫情大流行中，印度医疗系统一直在努力将不良后果控制在尽可能低的水平。本研究旨在分享印度北部一家专门收治新冠患者的三级政府医院管理合并症新冠患者的经验。
在印度北部一家专门收治新冠患者的三级医疗保健政府医院进行了一项回顾性观察研究。记录并评估了2020年4月至9月期间所有年龄组、男女不限、患有合并症且实验室确诊的新冠患者的社会人口统计学数据、住院数据和药物使用模式的详细信息。
在总共406名研究参与者中，共开出了2868种药物。其中，2336种用于管理新冠症状，532种用于管理并存的合并症。对于新冠症状，最常开具的药物类别是抗菌药物（853种，36.52%），其次是非甾体抗炎药（374种，16.01%）、质子泵抑制剂（299种，12.80%）、抗组胺药（232种，9.93%）、免疫抑制药物（103种，4.41%）等。对于合并症，最常开具的是抗高血压药物（310种，58.60%），其次是抗糖尿病药物（166种，31.38%）、支气管扩张剂（34种，6.43%）、甲状腺激素（11种，2.08%）、免疫抑制药物（7种，1.32%）。
最常开具的抗高血压药物是钙通道阻滞剂（CCB），开具最少的是β受体阻滞剂+CCB。在抗糖尿病药物中，最常开具的是胰岛素，开具最少的是二肽基肽酶-4（DPP-4）抑制剂以及双胍类+DPP-4抑制剂。
